Drug Trial Radar · NCT07185243
A Study to Evaluate Combination Therapy of Oncolytic Vaccinia Virus (hV01) and PD-1 Inhibitor in Advanced Solid Tumors.
Last checked: Nov 20, 2026Latest source record: Nov 20, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
24
Planned (sponsor's estimate)
Start
Jun 23, 2025
Primary completion
Jun 2027
Study completion Jun 2028
Sponsor
- Lead sponsor
- Hangzhou Converd Co., Ltd.Industry
- Sponsor type
- Industry
- Collaborators
- Xiamen Humanity Hospital
- First posted
- Sep 22, 2025
Design
- Study type
- Interventional
- Phase
- Not applicable
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate the safety and primary efficacy of the combination therapy of recombinant human IL-21-expressing oncolytic vaccinia virus (hV01) and the PD-1 Inhibitor Tislelizumab in patients with advanced solid tumors.
Conditions
- Advanced Solid Tumors
Interventions
recombinant human IL-21-expressing oncolytic vaccinia virus injectionBiological
hV01 is a recombinant vaccinia virus with deletions of the viral thymidine kinase (TK) and viral growth factor (VGF) genes and insertion of the human IL-21 gene.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Dose-limiting toxicitiesTime frame: From the first hV01 dose till the end of cycle 1 (each cycle is 28 days in Part A and 42 days in Part B of the study).
- Adverse eventsTime frame: From informed consent to approximately 3 months after the End of Treatment (EOT).
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Xiamen Humanity Hospital
Xiamen, Fujian, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.